Spruce Biosciences Inc
SPRB
查看详细走势图
72.400USD
+1.550+2.19%
收盘 02/06, 16:00（美东）报价延迟15分钟
40.80M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.19%
5天
-6.64%
1月
-10.14%
6月
+55678.12%
今年开始到现在
-16.89%
1年
0.00%
查看详细走势图
TradingKey Spruce Biosciences Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Spruce Biosciences Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名203/392位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价230.50。中期看，股价处于下降通道。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Spruce Biosciences Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Spruce Biosciences Inc亮点
亮点风险
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical need. The Company has acquired an exclusive worldwide license agreement for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). The TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with modified human insulin-like growth factor 2 via an amino acid linker. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. The Company's pipeline also includes Tildacerfont and Cortibon for the treatment of Major Depressive Disorder, SPR202 for the treatment of Congenital Adrenal Hyperplasia and SPR204 for the treatment of Post-Bariatric Hypoglycemia.
业绩增长期
公司处于发展阶段，最新年度总收入4.91M美元
估值合理
公司最新PE估值-0.86，处于3年历史合理位
机构减仓
最新机构持股471.88K股，环比减少0.47%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值0.00
分析师目标
根据
4
位分析师
强力买入
评级
230.500
目标均价
+225.34%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Spruce Biosciences Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Spruce Biosciences Inc简介
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical need. The Company has acquired an exclusive worldwide license agreement for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). The TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with modified human insulin-like growth factor 2 via an amino acid linker. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. The Company's pipeline also includes Tildacerfont and Cortibon for the treatment of Major Depressive Disorder, SPR202 for the treatment of Congenital Adrenal Hyperplasia and SPR204 for the treatment of Post-Bariatric Hypoglycemia.
公司代码SPRB
公司Spruce Biosciences Inc
CEOSzwarcberg (Javier)
网址https://sprucebio.com/
相关品种
